Cognition Therapeutics, Inc. (CGTX) Investor Relations Documents

Cognition Therapeutics, Inc. (CGTX) investor relations documents from the company's IR site: 1 presentation, 17 press releases; latest deck 2026-03-25. Read in-app with summaries. First-party data.

https://ir.cogrx.com/wp-content/uploads/2026/03/March-CGTX-corporate-deck-0326-2026.pdf: Zervimesine is an oral, once-daily small molecule oligomer antagonist advancing toward Phase 3 trials for the treatment of dementia with Lewy bodies (DLB) psychosis.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-06Press releaseCognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update
2026-07-13Press releaseCognition Therapeutics Participating in Fireside Chat at B. Riley Securities’ Mind, Muscle & Vision Summit
2026-06-24Press releaseCognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receip
2026-06-16Press releaseCognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervi
2026-06-01Press releaseCognition Therapeutics Participating in Upcoming Investor Conferences
2026-05-21Press releaseCognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis
2026-05-14Press releaseCognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine
2026-05-07Press releaseCognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update
2026-04-07Press releaseCognition Therapeutics to Present at Needham Virtual Healthcare Conference
2026-03-31Press releaseCognition Therapeutics CEO Issues Letter to Shareholders
2026-03-26Press releaseCognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update
2026-03-25Presentationhttps://ir.cogrx.com/wp-content/uploads/2026/03/March-CGTX-corporate-deck-0326-2026.pdf
2026-03-23Press releaseCognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results
2026-03-17Press releaseCognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodi
2026-03-02Press releaseCognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis
2026-02-05Press releaseCognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
2026-01-27Press releaseCognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies
2026-01-06Press releaseCognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dem

CGTX overview · CGTX earnings · CGTX financials · CGTX KPIs · CGTX ownership · CGTX peers · CGTX filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.